MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/inf.0000000000003608

Медицинская библиотека · The Pediatric infectious disease journal · 2022

Mucormycosis in Children With Hematologic Malignancies: A Case Series and Review of the Literature.

Loeffen Yvette G T, Scharloo Fenna, Goemans Bianca F, Heitink-Polle Katja M J, Lindemans Caroline A, van der Bruggen Tjomme, Hagen Ferry, Wolfs Tom F W

СтатьяОбзорПеревод пока не подготовлен

Аннотация

BACKGROUND

Mucormycosis is classified as the third leading cause of invasive fungal disease in immunocompromised patients and is characterized by high morbidity and mortality (33%-56%). The aim of this study is to describe presentation, treatment and outcome of Dutch pediatric hemato-oncology patients recently diagnosed with mucormycosis and to review the literature to gain more insight specifically into contemporary outcome data.

METHODS

Ten cases were diagnosed in the Princess Máxima Center for Pediatric Oncology from 2018 to 2021 and were retrospectively reviewed. In addition, 9 case series (n = 148) were included from literature.

RESULTS

In our case series, 5 patients of 10 children (age 2-17 years) had disseminated invasive fungal disease. Four patients had localized pulmonary disease and 1 had a localized renal infection. One diagnosis was made postmortem. The underlying diseases were acute lymphoblastic leukemia (n = 6), acute myeloid leukemia (n = 2) and lymphoma (n=2). Seven patients received combination therapy comprising of a lipid amphotericin B formulation and a triazole, surgery was performed in 67%. All neutropenic patients received granulocyte transfusions and/or granulocyte colony-stimulating factor. Mucormycosis-related mortality was 20%. In the literature review, mucormycosis-related mortality was 36% for all patients and 66% for patients with disseminated disease. Survival rates were similar over the past 2 decades. The most common underlying disorder was acute lymphoblastic leukemia. Liposomal amphotericin B was the mainstay of treatment. Seventy percent of patients underwent surgery.

CONCLUSIONS

Although survival of mucormycosis improved significantly overtime, it plateaued in the past decades. This series shows that with screening, early diagnostics and early antifungal and if possible surgical treatment, mortality is low and even disseminated disease is salvageable if approached aggressively with a combination of surgery and antifungal treatment. Further research focused on diagnostics, combination antifungal and adjunctive therapy is necessary to enhance the survival of mucormycosis in children.

Для цитирования: Loeffen Yvette G T, Scharloo Fenna, Goemans Bianca F, Heitink-Polle Katja M J, Lindemans Caroline A, van der Bruggen Tjomme, Hagen Ferry, Wolfs Tom F W. Mucormycosis in Children With Hematologic Malignancies: A Case Series and Review of the Literature.. The Pediatric infectious disease journal. 2022. DOI: 10.1097/inf.0000000000003608.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.